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Patients Characteristics (N 5 18)
Sex: Male/Female 10/8
Median Age (years) 50 (range: 32–62)
Race
Caucasians 15
African Americans 3
Diagnosis
APL 1
HD 1
NHL 8
MM 8
Median CD341 Cells/kg 7.57 million
(range: 2.93–76.16)
APL: Acute Promyelocytic Leukemia, HD: Hodgkin Disease,
MM: Multiple Myeloma, NHL: Non-Hodgkin Lymphoma.
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TOTAL BODY IRRADIATION BASED (TBI) VERSUS CHEMOTHERAPY-
BASED-PREPARATIVE REGIMENS BEFORE AUTOLOGOUS STEM CELL
TRANSPLANTS FOR NON-HODGKIN’S LYMPHOMA
Liu, H.1, Seftel, M.2, Demers, A.3, Schroeder, G.1, Nugent, Z.3,
Butler, J.1, Rubinger, M.2 1CancerCare Manitoba, University of Mani-
toba, Winnipeg, MB, Canada; 2CancerCare Manitoba, University of
Manitoba, Winnipeg, MB, Canada; 3CancerCare Manitoba, Winnipeg,
MB, Canada.
Objectives: The optimum high dose preparative regimen for
non-Hodgkin lymphoma (NHL) patients undergoing autologous
stem cell transplantation (ASCT) is unknown.We compared the ra-
diation-based regimen of cyclophosphamide, etoposide and 12 Gy
total body irradiation (CY/E/TBI) to carmustine, etoposide, cytar-
abine and melphalan (BEAM) in NHL patients who received
ASCT. We investigated acute and long-term toxicities, disease
free survival (DFS), overall survival (OS) of these two regimens.
Methods: Historical cohort study was performed at a provincial
cancer centre. Cause specific survival was determined with the Ka-
plan-Meier method. Suvival between groups was compared using
the log-rank test.Results:FromMar-1991 to Sep-2005, 79 patients
received CY/E/TBI (n5 32) or BEAM (n5 47). Histology was in-
dolent in 30 and aggressive in 49 patients. Cell source was bone
marrow in six and 73 received peripheral blood progenitor cells.
Prior to ASCT, ten patients were in complete remission, 47 had
chemo-sensitive disease and 22 had chemo-resistant disease. There
were only two cases of interstitial pneumonitis, with one in each
preparative regimen group. There were six transplant related
deaths; two in the BEAM group and four were in TBI group. The
TBI based group has a higher mean mucosits score (p 5 0.03).
Five year DFS was 47% and 51% in the TBI and BEAMgroups, re-
spectively (p 5 0.41). Five year OS was 50% and 64% for the TBI
and BEAM based groups (p5 0.07). Multivariate analyses revealed
that patients with more advanced disease status and raised LDH at
ASCT independently predicted inferiorDFS. There was one case of
acute myeloid leukemia and two of prostate cancer, all of whom
were in the TBI group. Conclusions: As compared to a BEAM
based regimen, a 12 Gy TBI-based regimen resulted in a similar
DFS. The TBI group had a trend toward poorer OS than
a BEAM-based regimen that may accounted for by other confound-
ing variables. There did not appear to be excess pulmonary or other
acute toxicities in the TBI based group. Randomized controlled tri-
als are required in order to establish the superiority of either
regimen.103
HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT): A SINGLE CEN-
TER EXPERIENCE IN COLOMBIA
Abello, V., Rosales, C., Pedraza, E., Esguerra, H.J., Rosales, M.L.,
Linares, A. Clınica de Marly, Bogota, Colombia.Here we report the results of autologous and allogenic SCT in
a single institution in Bogota, Colombia, between 1993 and 2007.
We performed 532 SCT in 526 patients, 227 allogenic and 305
autologous.
In 294 (96.4%) of autologous-SCT, stem cells were obtained
from peripheral blood.Mean 2.97 106/kg (0.31–30) CD341 cells,
in 3 (1–8) apheresis, were collected. 224 (73.7%) were movilized us-
ing Cyclofosfamide plus G-SCF. The rest were movilized with var-
ious chemotherapy regimens or G-CSF alone. Indications for auto-
SCT were: Non-Hodgkins Lymphoma 115, Hodgkin disease 93,
multiple myeloma 59, solid tumors 18, acute leukemias 17, other
3. Mean age was 40.1 years (5–68). 189 (61.9%) were male. Most
common conditioning regimens for lymphomas were BEAM and
BEM. All MM patients were conditioned with Melphalan 200
mg/m2. Hospitalization median time was 27 days (14–87). Day
100 TRM (transplant related mortality) was 6.23%. At mean
31.23 months (0.16–161) follow up overall and relapse free survival
are 71% and 66.4% respectively. 60% of deaths were related to dis-
ease relapse.
Of 227 allo-SCT, in 214 SC were obtained from peripheral
blood, only 13 were obtained from bone marrow. 153 (59%) were
males. Most common indications for transplant were: Chronic
myeloid leukemia 57, acute myeloid leukemia 46, acute lymphoid
leukemia 41, bone marrow failure syndromes 44, Hodgkin’s and
non-Hodgkin lymphomas 14, MDS 9, other 12. Mean age was
30.1 (4–63) years. 72% of patients and 76% of donors were IgG
CMV positive. Most common conditioning regimens for acute
leukemias and lymphomas were BuCy, BuCy-etoposide, busulfan-
fludarabine; and for aplastic anemia high dose cyclofosfamide or cy-
clophosphamide plus ATG. Hospitalization median time was 34
days (17–103). Day 100 TRM was 16.7%. At mean 25.72 months
(0.27–147) follow up, overall and relapse free survival are 53.2%
and 50.9% respectively.
Results described here are similar of ones reported in other cen-
ters around de world, they confirm that SCT is feasible in centers of
developing world.104
PITUITARY APOPLEXY COMPLICATING AUTOLOGOUS STEM CELL
TRANSPLANTATION
Ling Cheng, K., Devoe, C., John, V., Kiner, B., Cannon, M.,
Gissinger, D., Klocke, J., Bayer, R.-L. North Shore University Hospital,
Manhasset, NY.
Pituitary Apoplexy (PA) is an uncommon neurologic event that
results from sudden hemorrhage or infarction of the pituitary gland.
Most of these events occur in patients with undiagnosed pituitary
adenoma. There are various precipitating causes. We report
a case of PA precipitated by thrombocytopenia during autologous
stem cell transplantation.
The patient is a 48M with history of stage II multiple myeloma
initially treated with lenalidomide and dexamethasone. The patient
then proceeded to Auto PSCT. His preparative regimen consisted
of melphalan 200 mg/m2. Initial lab values showed a platelet count
of 429K/ul. The patient became febrile on Day 4 and was started on
broad spectrum antibiotics. Voriconazole replaced fluconazole
when fevers persisted. On Day 7, the patient complained of blurry
vision. This was the first day plts were below 10K/ul. A possible cul-
prit was voriconazole and it was discontinued. The patient com-
plained his peripheral vision was particularly compromised, and
bitemporal hemianopsia was confirmed. CT of the brain revealed
a 2.3 2.5 cmhemorrhagic pituitarymass. Platelets were transfused
to keep plts above 75K/ul. Hydrocortisone was begun, as was des-
mopressin, for developing diabetes insipidus.MRI confirmed a large
suprasellar mass consisitent with a pituitary macroadenoma that
contained hemorrhage. The incidence of PA with pituitary ade-
noma is variable, but has been reported to be as high as 27.7%.
Many patients have nonfunctional adenomas or are asymptomatic
prior to the event. Clinical symptoms of PA are also variable but
the most common symptoms include headache, nausea, and visual
deficits. As in most cases, our patient had an undiagnosed pituitary
adenoma and was asymptomatic. The thrombocytopenia and im-
munocomprimise of PSCT can make the pituitary vulnerable to
hemorrhage and abscess, both reported causes of apoplexy.
